Early Combination Therapy for the Treatment of Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis
These results suggest a potential benefit of initial combination therapy on glycemic outcomes in diabetes compared to metformin monotherapy across a wide range of baseline A1c levels. Further research should explore if early combination treatment may also affect longer term health outcomes in diabetes (Diabetes, Obesity and Metabolism)
Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes?
Treatment quality indicators measuring lipid- and albuminuria-lowering treatment status are valid quality measures, since they predict a lower risk of cardiovascular events and mortality in patients with diabetes. The quality indicators for glucose-lowering treatment should only be used for restricted populations with elevated HbA1c levels. Intriguingly, the tested indicators for blood pressure-lowering treatment did not predict patient outcomes (PLoS ONE)
Intensification of medication and glycaemic control among patients with type 2 diabetes – the ADVANCE trial
Effective glycaemic control was associated with treatment intensification at lower HbA1c levels at all stages of the disease course and in both arms of the ADVANCE trial (Diabetes, Obesity and Metabolism)